Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin

References

• National Kidney FoundationKDOQI clinical practice guideline for diabetes and CKD: 2012 updateAm J Kidney Dis20126085088623067652
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ2000321725840541210938048
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE)Guidance. Type 2 diabetes: The management of type 2 diabetes. NICE guidelines [CG87] Available from: http://www.nice.org.uk/guidance/cg87/chapter/guidanceAccessed March 25, 2015
   Google Scholar
• ScheenAJPharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney diseaseExpert Opin Drug Metab Toxicol20139552955023461781
   PubMed Web of Science ®Google Scholar
• DeaconCHughesTHolstJJDipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pigDiabetes1998477647699588448
   PubMed Web of Science ®Google Scholar
• MentleinRGallwitzBSchmidtWDipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEur J Biochem19932148298358100523
   PubMedGoogle Scholar
• DruckerDNauckMThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet20063681696170517098089
   PubMed Web of Science ®Google Scholar
• NauckMAKleineNOrskovCHolstJJWillmsBCreutzfeldtWNormalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patientsDiabetologia19933687417448405741
   PubMed Web of Science ®Google Scholar
• SteinSALamosEMDavisSNA review of the efficacy and safety of oral antidiabetic drugsExpert Opin Drug Saf201312215317523241069
   PubMed Web of Science ®Google Scholar
• SeckTNauckMShengDSitagliptin Study 024 GroupSafety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyInt J Clin Pract201064556217620456211
   PubMed Web of Science ®Google Scholar
• MatthewsDRDejagerSAhrenBVildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year studyDiabetes Obes Metab201012978078920649630
   PubMed Web of Science ®Google Scholar
• GökeBGallwitzBErikssonJGHellqvistÅGause-NilssonISaxagliptin vs glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trialInt J Clin Pract201367430731623638466
   PubMed Web of Science ®Google Scholar
• GallwitzBRosenstockJRauchT2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trialLancet2012380984047548322748821
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia201558342944225583541
   PubMed Web of Science ®Google Scholar
• ForstTPfütznerALinagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetesExpert Opin Pharmacother201213110111022149370
   PubMed Web of Science ®Google Scholar
• ThomasLEckhardtMLangkopfETadayyonMHimmelsbachFMarkM(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitorsJ Pharmacol Exp Ther200832517518218223196
   PubMed Web of Science ®Google Scholar
• EckhardtMHauelNHimmelsbachF3,5-Dihydroimidazo[4,5-d] pyridazin-4-ones: a class of potent DPP-4 inhibitorsBioorg Med Chem Lett2008183158316218485703
   PubMed Web of Science ®Google Scholar
• GallwitzBSmall molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapyExpert Opin Investig Drugs201120723732
   PubMed Web of Science ®Google Scholar
• FuchsHTillementJUrienSGreischelARothWConcentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humansJ Pharm Pharmacol200961556219126297
   PubMed Web of Science ®Google Scholar
• HeiseTGraefe-ModyEHuttnerSRingATrommeshauserDDugiKPharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patientsDiabetes Obes Metab20091178679419476474
   PubMed Web of Science ®Google Scholar
• Graefe-ModyEJungnikARingAWoerleHDugiKEvaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteersInt J Clin Pharmacol Ther20104865266120875371
   PubMed Web of Science ®Google Scholar
• HuttnerSGraefe-ModyEWithopfBRingADugiKSafety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteersJ Clin Pharmacol2008481171117818812608
   PubMed Web of Science ®Google Scholar
• FriedrichCEmserAWoerleHJGraefe-ModyURenal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetesAm J Ther201320661862123411609
   PubMed Web of Science ®Google Scholar
• GallwitzBSafety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factorsTher Adv Endocrinol Metab2013439510523730503
   PubMedGoogle Scholar
• FriedrichCRingABrandTSennewaldRGraefe-ModyEUWoerleHJEvaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteersEur J Drug Metab Pharmacokinet201136172421340661
   PubMed Web of Science ®Google Scholar
• Del PratoSBarnettAHHuismanHNeubacherDWoerleHJDugiKAEffect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trialDiabetes Obes Metab20111325826721205122
   PubMed Web of Science ®Google Scholar
• KawamoriRInagakiNArakiELinagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind studyDiabetes Obes Metab201214434835722145698
   PubMed Web of Science ®Google Scholar
• TaskinenMRRosenstockJTamminenISafety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled studyDiabetes Obes Metab201113657421114605
   PubMed Web of Science ®Google Scholar
• OwensDRSwallowRDugiKAWoerleHJEfficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized studyDiabet Med2011281352136121781152
   PubMed Web of Science ®Google Scholar
• GallwitzBRosenstockJPatelSRegardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trialDiabetes Obes Metab201517327628425425502
   PubMed Web of Science ®Google Scholar
• GallwitzBRosenstockJEmserAvon EynattenMWoerleHJLinagliptin is more effective than glimepiride at achieving a composite outcome of target HbA1c < 7% with no hypoglycaemia and no weight gain over 2 yearsInt J Clin Pract201367431732123521323
   PubMed Web of Science ®Google Scholar
• HaakTMeinickeTJonesRWeberSvon EynattenMWoerleHJInitial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension studyInt J Clin Pract201367121283129324118640
   PubMed Web of Science ®Google Scholar
• HaakTCombination of linagliptin and metformin for the treatment of patients with type 2 diabetesClin Med Insights Endocrinol Diabetes201581625628514
   PubMedGoogle Scholar
• RossSACaballeroAEDel PratoSInitial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trialDiabetes Obes Metab201517213614425298165
   PubMed Web of Science ®Google Scholar
• BlechSLudwig-SchwellingerEGrafe-ModyEWithopfBWagnerKThe metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humansDrug Metab Dispos20103866767820086031
   PubMed Web of Science ®Google Scholar
• MorishitaRNakagamiHTeneligliptin: expectations for its pleiotropic actionExpert Opin Pharmacother201516341742625597385
   PubMed Web of Science ®Google Scholar
• DeaconCHolstJLinagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetesExpert Opin Investig Drugs201019133140
   PubMed Web of Science ®Google Scholar
• Graefe-ModyUFriedrichCPortAEffect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptinDiabetes Obes Metab20111393994621672124
   PubMed Web of Science ®Google Scholar
• OtsukiHKosakaTNakamuraKShimomuraFKuwaharaYTsukamotoTSafety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetesInt Urol Nephrol201446242743224014134
   PubMed Web of Science ®Google Scholar
• KothnyWShaoQGroopPLukashevichVOne-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairmentDiabetes Obes Metab2012141032103922690943
   PubMed Web of Science ®Google Scholar
• NowickiMRychlikIHallerHLong-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety studyInt J Clin Pract2011651230123921977965
   PubMed Web of Science ®Google Scholar
• McGillJSloanLNewmanJLong-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled studyDiabetes Care20133623724423033241
   PubMed Web of Science ®Google Scholar
• GomisREspaderoRJonesRWoerleHDugiKEfficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled studyDiabetes Obes Metab20111365366121410628
   PubMed Web of Science ®Google Scholar
• NowickiMRychlikIHallerHWarrenMSuchowerLGause-NilssonISaxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairmentDiabetes Obes Metab20111352353221332627
   PubMed Web of Science ®Google Scholar
• MeyersJCandrilliSKovacsBType 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustmentPostgrad Med201112313314321566423
   PubMed Web of Science ®Google Scholar
• MonnierLLapinskiHColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c)Diabetes Care20032688188512610053
   PubMed Web of Science ®Google Scholar
• RitzELimitations and future treatment options in type 2 diabetes with renal impairmentDiabetes Care201134Suppl 2S330S33421525478
   PubMedGoogle Scholar
• LaaksoMRosenstockJGroopPHTreatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trialDiabetes Care2015382e15e1725614693
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim BI Trial Nr. 1218.64 1. – 15. CTR Main Part Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.64_U13-1283-01-DS.pdfAccessed March 25, 2015
   Google Scholar
• Arjona FerreiraJCCorryDMogensenCEEfficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trialAm J Kidney Dis201361457958723352379
   PubMed Web of Science ®Google Scholar
• Arjona FerreiraJCMarreMBarzilaiNEfficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiencyDiabetes Care20133651067107323248197
   PubMed Web of Science ®Google Scholar
• ChanJCScottRArjona FerreiraJCSafety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyDiabetes Obes Metab20081054555518518892
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet19983528548659742977
   PubMed Web of Science ®Google Scholar
• OhkuboYKishikawaHArakiEIntensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Res Clin Pract1995281031177587918
   PubMed Web of Science ®Google Scholar
• BakrisGRecognition, pathogenesis and treatment of different stages of nephropathy in patients with type 2 diabetes mellitusMayo Clin Proc20118644445621531886
   PubMed Web of Science ®Google Scholar
• ShrishrimalKHartPMichotaFManaging diabetes in hemodialysis patients: observations and recommendationsCleveland Clin J Med200976649655
   PubMed Web of Science ®Google Scholar
• ChapelskyMThompson-CulkinKMillerASackMBlumRFreedMPharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiencyJ Clin Pharmacol20034325225912638393
   PubMed Web of Science ®Google Scholar
• SchwarzBGouveiaMChenJCost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapyDiabetes Obes Metab200810Suppl 1435518435673
   PubMed Web of Science ®Google Scholar
• MarxNRosenstockJKahnSEDesign and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)Diab Vasc Dis Res201512316417425780262
   PubMed Web of Science ®Google Scholar